The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Clinical Evidence of Herbal Drugs As Perpetrators of Pharmacokinetic Drug Interactions
Open accessAbstract
The use of herbal/botanical products, also referred to as complementary and alternative medicines (CAM), worldwide enjoys increasing popularity. It appears in particular highly prevalent in patient populations already exposed to complex treatment algorithms and polypharmacotherapy, frequently involving narrow therapeutic index drugs. Accordingly, the potential clinical dimension and relevance of herb-drug interactions has received considerable attention over the last years. However, review of pertinent literature indicates that the available clinical evidence in this regard is still limited and sometimes inconclusive. Also, communication of herb-drug interaction data in the biopharmaceutical/medical literature is often complex and confusing, not always unbiased, and in many cases appears not to strive for clear-cut and useful guidance in terms of the clinical relevance of such findings.This systematic review summarizes and interprets the published evidence on clinical herb-drug interaction studies which examined the potential of six popular herbal drugs (Echinacea, garlic, gingko, ginseng, goldenseal, and milk thistle) as perpetrators of pharmacokinetic (PK) drug interactions. Reported effect sizes were systematically categorized according to FDA drug interaction guideline criteria. A total of 66 clinical PK interaction studies, meeting the scope of the present review, were identified. The clinical evidence was found to be most robust and informative for Gingko biloba (GB; 21 studies) and milk thistle/silymarin (MT; 13), and appears still limited for ginseng (9), goldenseal/berberine (GS; 8), garlic (8), and Echinacea (7). Collectively, the available evidence indicates that, at commonly recommended doses, none of these herbs act as potent or moderate inhibitors or inducers of cytochrome P450 (CYP) enzymes or P-glycoprotein (ABCB1). Weak effects in terms of either induction or inhibition were found for GB (presystemic/hepatic CYP3A4 induction/inhibition, CYP2C19 induction at high doses), milk thistle/silymarin (CYP2C9 inhibition), GS/berberine (CYP3A4 and CYP2D6 inhibition), Echinacea (presystemic/hepatic CYP3A4 inhibition/induction, CYP1A2 and CYP2C9 inhibition at high doses). Information was found not always complete for the major drug metabolizing CYP enzymes in the less well-studied herbs and is largely limited to P-glycoprotein (ABCB1) when effects on drug transporters have been investigated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kaufman, D. W., Kelly, J. P., Rosenberg, L., Anderson, T. E., & Mitchell, A. A. (2002) · JAMA · doi:10.1001/jama.287.3.337 · Cited by 1,845
Interactions Between Herbal Medicines and Prescribed Drugs: An Updated Systematic Review
Izzo, A. A., & Ernst, E. (2009) · Drugs · doi:10.2165/11317010-000000000-00000 · Cited by 801
GURLEY, B., GARDNER, S., HUBBARD, M., WILLIAMS, D., GENTRY, W., KHAN, I., & SHAH, A. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.01.009 · Cited by 271
Gurley, B. J., Swain, A., Hubbard, M. A., Williams, D. K., Barone, G., Hartsfield, F., Tong, Y., Carrier, D. J., Cheboyina, S., & Battu, S. K. (2008) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200600300 · Cited by 169
Repeated administration of berberine inhibits cytochromes P450 in humans
Guo, Y., Chen, Y., Tan, Z.-R., Klaassen, C. D., & Zhou, H.-H. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1108-2 · Cited by 137
Etheridge, A., Black, S., Patel, P., So, J., & Mathews, J. (2007) · Planta Medica · doi:10.1055/s-2007-981550 · Cited by 102 · cited 1×
“In contrast, there is no conclusive in vitro evidence that MT would have significant effects on the activity of P ‑ gp (ABCB1) [45,48].”
Lee, L. S., Andrade, A. S. A., & Flexner, C. (2006) · Clinical Infectious Diseases · doi:10.1086/507894 · Cited by 102
Gurley, B. J., Swain, A., Hubbard, M. A., Hartsfield, F., Thaden, J., Williams, D. K., Gentry, W. B., & Tong, Y. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100222 · Cited by 102
Wu, X., Li, Q., Xin, H., Yu, A., & Zhong, M. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0952-3 · Cited by 90
The effects of berberine on the pharmacokinetics of ciclosporin A in healthy volunteers
Xin, H.-W., Wu, X.-C., Li, Q., Yu, A.-R., & Zhong, M.-Y. (2006) · Methods and Findings in Experimental and Clinical Pharmacology · doi:10.1358/mf.2006.28.1.962774 · Cited by 63
Cited by
Interindividual Differences in Caffeine Metabolism and Factors Driving Caffeine Consumption
Nehlig, A. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014407 · Cited by 632
Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics
Feng, X., Sureda, A., Jafari, S., Memariani, Z., Tewari, D., Annunziata, G., Barrea, L., Hassan, S. T. S., Šmejkal, K., Malaník, M., et al. (2019) · Theranostics · doi:10.7150/thno.30787 · Cited by 465
Inhibition and induction of CYP enzymes in humans: an update
Hakkola, J., Hukkanen, J., Turpeinen, M., & Pelkonen, O. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02936-7 · Cited by 418
Adverse Effects of Nutraceuticals and Dietary Supplements
Ronis, M. J. J., Pedersen, K. B., & Watt, J. (2018) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052844 · Cited by 360
Traditional use and safety of herbal medicines1
Moreira, D. D. L., Teixeira, S. S., Monteiro, M. H. D., De-Oliveira, A. C. A. X., & Paumgartten, F. J. R. (2014) · Revista Brasileira de Farmacognosia · doi:10.1016/j.bjp.2014.03.006 · Cited by 266
Metadata
- Authors
- Hermann, R., & von Richter, O.
- Venue
- Planta Medica
- Publisher
- Georg Thieme Verlag KG
- Published
- 2012-08-01
- Volume
- 78
- Issue
- 13
- Pages
- 1458-1477
- ISSN
- 0032-0943 (ISSN-L)
- 1439-0221
- OpenAlex
- W2054410567
- Cited by
- 197
- References
- 11
- FWCI
- 41.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Evidence of Herbal Drugs As Perpetrators of Pharmacokinetic Drug Interactions. https://app.cochat.ai/papers/10.1055/s-0032-1315117
- The paper
- Hermann, R., & von Richter, O. (2012). Clinical Evidence of Herbal Drugs As Perpetrators of Pharmacokinetic Drug Interactions. Planta Medica. https://doi.org/10.1055/s-0032-1315117
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.